Shares of Editas Medicine Inc. (NASDAQ:EDIT) traded down 4.3% during trading on Wednesday . The company traded as low as $18.87 and last traded at $19.09, with a volume of 176,522 shares trading hands. The stock had previously closed at $19.94.

A number of analysts have commented on the stock. Cowen and Company reiterated a “buy” rating on shares of Editas Medicine in a research note on Monday, May 16th. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th. Vetr upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target for the company in a research note on Monday, May 9th. Finally, Jefferies Group reiterated a “hold” rating and issued a $35.00 price target on shares of Editas Medicine in a research note on Friday, June 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Editas Medicine presently has a consensus rating of “Hold” and a consensus price target of $33.50.

The stock has a 50 day moving average price of $24.71 and a 200-day moving average price of $29.50. The company’s market capitalization is $674.80 million.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). On average, equities analysts forecast that Editas Medicine Inc. will post ($2.61) earnings per share for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.